Real estate
Teva Pharmaceutical is in the midst of a $3 billion cost-cutting plan that includes cutting jobs worldwide. New Jersey has approved a plan that would save 1,000 jobs in New Jersey and relocate the company’s U.S. headquarters to Parsippany.
Eisai Inc. is adding to its arsenal aimed at combating dementia. The company will launch the Eisai Center for Genetics Guided Dementia Discovery.
For the last several years New York has been building itself up to be the biggest biotech hub on the east coast.
It’s not exactly breaking news that in the U.S., the two top spots for biotech companies are Boston and San Francisco. But now there’s even more weight to that statement, as French company Ipsen announced it plans to relocate its U.S. operations from New Jersey to Kendall Square in Cambridge, Massachusetts. The announcement was made at the 2018 BIO International Convention in Boston.
There are several recent announcements of German companies opening laboratories in the U.S.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Although it may be almost heresy to say it to venture capitalists and many research scientists, there are other places in the U.S. to form biotech companies than San Francisco and Boston.
In late March, Novo Nordisk broke ground on a new manufacturing facility in rural Clayton, North Carolina.
The Australian biotech market, which was valued at nearly $23 billion last year, is expected to see some positive growth to $25.2 billion by 2025, according to a GlobalData analysis.
PRESS RELEASES